Side-by-side comparison of AI visibility scores, market position, and capabilities
Senior living and long-term care management software for skilled nursing, assisted living, and home health organizations. Minneapolis, MN. Acquired by ResMed.
MatrixCare is a Minneapolis, Minnesota-based provider of electronic health record and business management software for the senior living and post-acute care market. Acquired by ResMed (NYSE: RMD) in 2018, MatrixCare operates as ResMed's long-term care software division and serves over 15,000 care settings across skilled nursing facilities, senior living communities, home health agencies, and hospice providers. The platform provides EHR, billing, scheduling, and analytics capabilities designed for the clinical and operational complexity of long-term care.\n\nMatrixCare's product suite includes separate but integrated modules for skilled nursing, senior living (assisted living and memory care), home health, and hospice care, reflecting the different clinical workflows and regulatory requirements across these settings. The skilled nursing module addresses Medicare and Medicaid billing complexity, MDS documentation, and therapy management. The senior living module focuses on activity of daily living documentation, resident assessment tracking, and billing for private-pay and Medicaid waiver programs.\n\nResMed's acquisition of MatrixCare reflected the strategic importance of care coordination between home-based care (ResMed's core sleep therapy and respiratory device business) and facility-based post-acute care. The combined organization can offer integrated monitoring data from connected medical devices alongside clinical documentation in the EHR, positioning MatrixCare within ResMed's broader digital health strategy. MatrixCare competes directly with PointClickCare as the two dominant EHR platforms in the North American LTPAC market.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.